ERBB2 and neoplasm: Recent studies suggest that group of patients with HER2-ultralow BC is a highly heterogeneous group with a distinct biological profile and immune profile affecting patients’ outcomes and response to therapies.34 The varying tumor-immune profiles in BC subgroups indicate that targeted immunotherapy could be beneficial for certain patients, though these findings are still exploratory.